Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 3/20 | 0.52 |
| ▸ | GRIA4 | P48058 | 8/20 | 0.37 |
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18396198 | 1.00 | GRIA1 (0.52) | GRIA1GRIA4CA12CA14CA7 | |
| SCHEMBL18395991 | 0.89 | GRIA1 (0.59) | GRIA1GRIA4CA12CA14CA7 | |
| SCHEMBL18395996 | 0.89 | GRIA1 (0.59) | GRIA1GRIA4CA12CA14CA7 | |
| SCHEMBL2842451 | 0.83 | GRIA1 (0.56) | GRIA1GRIA4CA12CA14CA7 | |
| SCHEMBL23182182 | 0.79 | GRIA1 (0.56) | GRIA1GRIA4CA12CA14CA7 | |
| SCHEMBL18395287 | 0.77 | CA12 (0.39) | CA12CA14CA7CA9FNTA | |
| SCHEMBL18395291 | 0.77 | CA12 (0.39) | CA12CA14CA7CA9FNTA | |
| SCHEMBL18396116 | 0.75 | PTGES (0.38) | CA12CA14CA7CA9FNTA | |
| SCHEMBL18396121 | 0.75 | PTGES (0.38) | CA12CA14CA7CA9FNTA | |
| SCHEMBL13610004 | 0.75 | GRIA1 (0.75) | GRIA1GRIA4GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170022153-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022153-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | GRIA1 951/4885GRIA4 775/4885CA12 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.